ArticleBiology2026
Integrative Multi-Omics Reveal the Molecular Architecture and Systemic Burden of Metabolic Syndrome in a Brazilian Cohort.
Article in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Metabolic Syndrome (MetS) includes a complex cluster of metabolic disorders that significantly increases the risk for cardiovascular disease and Type 2 Diabetes Mellitus. This study aimed to elucidate the molecular architecture and systemic burden of MetS by integrating high-resolution plasma proteomics, metabolomics, and lipidomics. A cohort of 60 adult volunteers (n = 37 controls; n = 23 MetS) from Brazil was subjected to comprehensive clinical evaluation and multi-omics profiling. Clinical analysis identified HOMA-IR and triglycerides as primary predictors of MetS. FDR was used for multiple testing correction for all data. Untargeted proteomics identified 589 proteins, with 26 showing significant differential abundance, including the upregulated Intercellular Adhesion Molecule-1 (ICAM-1) and Vanin-1 and the depleted protective Apolipoprotein D (ApoD) in MetS. Metabolomic analysis resulted in the identification of 410 metabolites, with 27 distinct features, revealing accumulation of branched-chain and aromatic amino acids, alongside a significant reduction in the signaling molecule 3-hydroxybutyrate, in the case group. Lipidomic profiling identified 1241 lipids, with 41 differentially abundant, highlighting the increase in Phosphatidylinositol (PI 40:5) and Phosphatidylcholine (PC) classes and the depletion of Sphingomyelins (SM). Integrative analysis demonstrated that MetS comprises a synchronized and multisystemic molecular disruption rather than a collection of independent risk factors. The homeostatic breakdown is characterized by the depletion of the body's antioxidant and anti-inflammatory defense, and the elevation of pro-inflammatory mediators like ICAM-1 and Vanin-1, the accumulation of lipotoxic drivers and a significant disruption in amino acid catabolism (BCAA) that overactivates the mTORC1 pathway. These findings provide a multifactorial metabolic dysregulation, offering putative signatures for future diagnoses and risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.